title: Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly.
abstract: Subanalysis of a pilot study (NCT01085318) assessed correlations between serum ferritin and imaging assessments in relapsing-remitting multiple sclerosis patients (n = 23) receiving 44 μg interferon beta-1a subcutaneously three times weekly. At baseline, 12, and 24 weeks, mean ferritin was 75, 127 (p < 0.001 vs baseline), and 101 (p=0.020 vs baseline) ng/mL. No relationship between ferritin and susceptibility-weighted imaging (SWI)-filtered phase of subcortical deep gray matter was found. Increasing ferritin correlated with decreasing lesion numbers on both fluid attenuated inversion recovery and SWI phase at 12 weeks (r = -0.62; p = 0.003; n = 21), and with decreasing gadolinium-enhancing lesion volume at 24 weeks (r = -0.71; p = 0.050; n = 8).
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA; MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 100 High St., Buffalo, NY 14203, USA. Electronic address: mgdwyer@bnac.net.
authors: Michael G
authors: MG
authors: Dwyer
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA; MR Imaging Clinical Translational Research Center, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 100 High St., Buffalo, NY 14203, USA. Electronic address: rzivadinov@bnac.net.
authors: Robert
authors: R
authors: Zivadinov
authors: Department of Neurology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC 27599, USA; Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, 125 Mason Farm Rd., 6109D Neuroscience Research Bldg, CB #7125, Chapel Hill, NC 27599, USA. Electronic address: markovics@neurology.unc.edu.
authors: Silva
authors: S
authors: Markovic-Plese
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA. Electronic address: npbergsland@bnac.net.
authors: Niels
authors: N
authors: Bergsland
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA. Electronic address: mari.hhb@live.com.
authors: Mari
authors: M
authors: Heininen-Brown
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA. Electronic address: ecarl@bnac.net.
authors: Ellen
authors: E
authors: Carl
authors: Buffalo Neuroimaging Analysis Center, Department of Neurology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA. Electronic address: ckennedy@bnac.net.
authors: Cheryl
authors: C
authors: Kennedy
authors: Baird MS Center, Department of Neurology, State University of New York at Buffalo, 100 High St., Buffalo, NY 14203, USA. Electronic address: Bweinstock-guttman@kaleidahealth.org.
authors: Bianca
authors: B
authors: Weinstock-Guttman
authors: EMD Serono, Inc., One Technology Pl., Rockland, MA 02370, USA. Electronic address: brooke.hayward@emdserono.com.
authors: Brooke
authors: B
authors: Hayward
authors: EMD Serono, Inc., One Technology Pl., Rockland, MA 02370, USA. Electronic address: fernando.dangond@emdserono.com.
authors: Fernando
authors: F
authors: Dangond
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D004198:Disease Susceptibility; D004334:Drug Administration Schedule; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D007279:Injections, Subcutaneous; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000097:blood* / Q000188:drug therapy*; D010865:Pilot Projects
chemical_list: D015415:Biomarkers; D016899:Interferon-beta; D005293:Ferritins; D000068556:Interferon beta-1a
keywords: Iron deposition; MRI; Multiple sclerosis